Schrödinger (SDGR) investor relations material

Market environment and customer trends

• Biotech funding and sentiment have improved significantly compared to last year, leading to new customer additions and business growth.

• Pharma companies have resumed R&D spending, moving away from previous budget freezes and focusing on technology investments.

• Efficiency and lean operations are prioritized in biotech, with computational tools enabling small teams to achieve major exits.

• Adoption gaps among top pharma customers are closing, with increased spend and new product trials.

• Disparities in technology spending among top pharma are driving broader adoption as companies seek to avoid being left behind.

Technology adoption and industry inflection

• The industry is in the early stages of large-scale adoption of computational and AI-driven drug discovery.

• Companies leveraging computation and AI are achieving faster, higher-quality development candidates.

• FOMO is accelerating adoption as success stories become public, with the sector expected to follow other industries transformed by computer-aided design.

• Both internal investment and external collaborations are pursued, with high-priority projects now involving substantial up-front commitments.

• Collaborations are increasingly used for know-how transfer, helping partners learn to deploy technology at scale.

Product innovation and rollout

• Bunsen, an agentic AI built on LLMs, will enter early access this summer, aiming to simplify complex workflows and scale adoption.

• Previewed to major customers, Bunsen received positive feedback and is expected to drive license consumption through throughput-based licensing.

• Predictive toxicology offering enables early computational screening for toxicity, reducing late-stage surprises and animal testing.

• The predictive tox panel will expand over time, with ongoing development to cover more targets.

• Early results show accurate replication of experimental screens and strong market receptivity.